Ipsen’s oral small molecule has failed to reduce the progression of a genetic disease that gradually turns tendons and ...

With all the buzzwords surrounding artificial intelligence, from smiling promotions to angry chagrins—promises that it will ...

Venture capital firm Aditum Bio is going all-out for a new collaboration with Fosun Pharma, launching a subsidiary with the ...

Earlier this month, Medtronic received a new approval from the FDA for its decades-old liquid embolic system, extending its ...

Merck & Co. is turning down its option to license Evaxion’s gonorrhea vaccine candidate, closing the door on the Danish ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Altimmune has shared an update on the metabolic dysfunction-associated steatohepatitis (MASH) study that sank its stock in June. The 48-week readout linked the top dose of the GLP-1/glucagon dual ...

Boehringer Ingelheim has turned down its chance to license Nxera Pharma’s phase 2-ready schizophrenia drug candidate, depriving the Japanese drugmaker of a 60 million euro ($70 million) option payment ...

After a long and strange year, Belgian biotech Galapagos is closing out 2025 with some mixed results for its last remaining ...

After taking a shot at becoming a neuroscience biotech, buzzy Bay Area AI outfit Verge Genomics is dropping its only clinical ...

Following years in development, the Finnish medtech GlucoModicum has unveiled its needle-free glucose monitoring patch, ...

A new mental health-driven biotech has arrived in Syremis Therapeutics. | Founded by a team of neuropsychiatric-focused Teva ...